MedTrace Logo

Bioequivalence Study Between YHP1906 Tab. 5 mg and YHR1902 Tab. 5 mg

NCT04316065 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-05-26

No results posted yet for this study

Summary

A randomized, open-label, single-dose, 2-sequence, 2-period, crossover clinical trial to investigate the bioequivalence between YHP1906 Tab. 5 mg and YHR1902 Tab. 5mg in healthy volunteers

Conditions

  • Healthy Volunteers

Interventions

DRUG

YHP1906

YHP1906 Tab. 5 mg

DRUG

YHR1902

Comparator. YHR1902 Tab. 5 mg

Sponsors & Collaborators

  • Metro Hospital

    collaborator UNKNOWN

  • Yuhan Corporation

    lead INDUSTRY

Principal Investigators

  • Sungdae Kwon · Metro Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-11
Primary Completion
2020-04-20
Completion
2020-04-24

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04316065 on ClinicalTrials.gov